E-Selectin Nasal Instillation to Prevent Secondary Stroke

Suspended

Phase 1 Results N/A

Summary of Purpose

This study will determine the maximum safe dose of the experimental drug E-selectin that can be given to stroke patients. E-selectin causes white blood cells called lymphocytes to change so that they prevent clots from forming in the vessels that supply blood to the brain. The drug has been shown to be effective in animal models of stroke. This study will look at the safety of using this experimental drug in...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 21 April 2018.

1 Oct 2003 12 Jul 2006 20 Nov 2025 20 Nov 2025 12 Mar 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Non-Randomized
  • Masking: Open Label
  • Purpose: Prevention
  • Endpoint: Safety Study
  • Intervention: Single Group Assignment

Contacts

  • Patient Recruitment and Public Liaison Office

    prpl@mail.cc.nih.gov (800) 411-1222

  • TTY

    1-866-411-1010

  • John M Hallenbeck, M.D.